Panacea Biotec Limited (IN:PANACEABIO)
:PANACEABIO
Want to see IN:PANACEABIO full AI Analyst Report?
PANACEABIO Stock Chart & Stats
₹358.50
-₹0.60(-0.13%)
At close: 4:00 PM EST
₹358.50
-₹0.60(-0.13%)
Day’s Range― - ―
52-Week Range₹293.10 - ₹647.50
Previous CloseN/A
Volume134.82K
Average Volume (3M)12.44K
Market Cap
₹33.54B
Enterprise Value₹24.88B
Total Cash (Recent Filing)₹1.28B
Total Debt (Recent Filing)₹229.00M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding61,250,744
10 Day Avg. Volume14,140
30 Day Avg. Volume12,438
Financial Highlights & Ratios
PEG Ratio9.41
Price to Book (P/B)2.16
Price to Sales (P/S)2.82
P/FCF Ratio-49.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and sizable, stable equity gives the company financial flexibility to fund R&D, manufacturing investment or absorb tender timing. This reduces refinancing risk and supports multi‑quarter resilience while cash flows recover, a durable stability lever.
Revenue RecoveryA multi-year revenue rebound (FY2026 about 40% higher than FY2023) signals renewed commercial traction across formulations and vaccines. Sustained top‑line growth supports scale benefits and provides a runway for margin recovery if costs are controlled.
Integrated Commercial & Manufacturing CapabilitiesOwning development, manufacturing and commercialization capabilities across vaccines and formulations creates durable competitive advantages: faster go‑to‑market, capture of manufacturing margin, and ability to serve institutional tenders and partners over multiple quarters.
Bears Say
Ongoing Operating LossesContinued net losses into FY2026 mean the company has not yet converted revenue growth into recurring profits. Persistent losses limit retained earnings, constrain reinvestment capacity over time, and heighten dependence on balance sheet resources.
Consistently Negative Free Cash FlowNegative free cash flow across multiple years indicates the business is consuming cash even if operating cash improved in FY2026. This structural cash absorption increases reliance on cash reserves or external funding, challenging long‑term self‑funding of growth.
Volatile Margins And Weak ReturnsVolatile margins and recurring negative EBIT imply the firm struggles to sustain pricing or cost discipline across cycles. This undermines return on invested capital and raises execution risk that revenue gains may not translate into durable profitability.
Panacea Biotec Limited News
PANACEABIO FAQ
What was Panacea Biotec Limited’s price range in the past 12 months?
Panacea Biotec Limited lowest stock price was ₹293.10 and its highest was ₹647.50 in the past 12 months.
What is Panacea Biotec Limited’s market cap?
Panacea Biotec Limited’s market cap is ₹33.54B.
When is Panacea Biotec Limited’s upcoming earnings report date?
Panacea Biotec Limited’s upcoming earnings report date is Aug 06, 2026 which is in 55 days.
How were Panacea Biotec Limited’s earnings last quarter?
Panacea Biotec Limited released its earnings results on May 30, 2026. The company reported ₹0.08 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.08.
Is Panacea Biotec Limited overvalued?
According to Wall Street analysts Panacea Biotec Limited’s price is currently Overvalued.
Does Panacea Biotec Limited pay dividends?
Panacea Biotec Limited pays a Annually dividend of ₹0.75 which represents an annual dividend yield of N/A. See more information on Panacea Biotec Limited dividends here
What is Panacea Biotec Limited’s EPS estimate?
Panacea Biotec Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Panacea Biotec Limited have?
Panacea Biotec Limited has 61,250,744 shares outstanding.
What happened to Panacea Biotec Limited’s price movement after its last earnings report?
Panacea Biotec Limited reported an EPS of ₹0.08 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.399%.
Which hedge fund is a major shareholder of Panacea Biotec Limited?
Currently, no hedge funds are holding shares in IN:PANACEABIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Panacea Biotec Limited
Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India, with operations segmented into Vaccines and Formulations. The company's pharmaceutical offerings comprise proprietary medicines targeting diverse medical fields such as pain management, diabetes, cardiovascular health, oncology, renal disease, osteoporosis, anti-tubercular therapy, and gastro-intestinal care. In addition to these, Panacea Biotec develops and distributes vaccines for conditions like anthrax, dengue, and Japanese encephalitis, among others. The firm maintains a robust global presence, exporting its goods to over 30 countries, including key markets such as the United States, Germany, the Russian Federation, Sri Lanka, and the Philippines. Notably, Panacea Biotec has established significant strategic alliances, including a partnership with the Russian Direct Investment Fund for the manufacture of the Sputnik-V COVID-19 vaccine. It also collaborates with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Translational Health Science and Technology Institute (THSTI) to pioneer vaccine candidates designed to combat SARS-CoV-2 variants and other beta coronaviruses.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Piramal Pharma Limited
―
Supriya Lifescience Limited
―
Syngene International Ltd.
―